---
title: "Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286575113.md"
description: "Incannex Healthcare Inc. reported Q1 2026 revenue of $0.09M and a net loss of $3.88M, with diluted EPS of $(0.35). This compares to a net loss of $3.97M and EPS of $(6.19) in the previous year. The company advanced its clinical pipeline, received FDA Fast Track designation for IHL-42X, and raised approximately $10M in a direct offering while maintaining a cash runway over one year."
datetime: "2026-05-15T13:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286575113.md)
  - [en](https://longbridge.com/en/news/286575113.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286575113.md)
---

# Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary

Incannex Healthcare Inc. reported first-quarter 2026 results with revenue of $0.09M and a net loss of $3.88M, or diluted EPS of $(0.35), compared with a net loss of $3.97M and diluted EPS of $(6.19) in the year-ago quarter.

**Financial Highlights**

-   Revenue was $0.09M for the quarter ended Mar 31, 2026, versus $0.00M in the year-ago quarter.
-   Net income was a loss of $3.88M for the quarter ended Mar 31, 2026, versus a loss of $3.97M in the year-ago quarter.
-   Diluted EPS was $(0.35) for the quarter ended Mar 31, 2026, versus $(6.19) in the year-ago quarter.

**Business Highlights**

-   Clinical pipeline advanced: Phase 2 dose-optimization for IHL-42X (obstructive sleep apnea) and Phase 2b dose-comparison for PSX-001 (generalized anxiety disorder).
-   Regulatory progress: IHL-42X granted FDA Fast Track designation; IND approval obtained for PsiGAD2 to support U.S. and U.K. Phase 2b trials.
-   R&D spending shifted: R&D expense declined following completion of an IHL-42X safety/pharmacokinetics trial, with R&D expected to increase as the DReAMzz program advances.
-   Capital actions: Raised approximately $10M in a March 2026 registered direct offering and executed share repurchases while maintaining a cash runway in excess of one year.
-   Partnerships: Continued investment in the Mind Clinics Australia joint venture to support clinical and operational expansion.

Original SEC Filing: Incannex Healthcare Inc. \[ IXHL \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IXHL.US](https://longbridge.com/en/quote/IXHL.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial](https://longbridge.com/en/news/287272648.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK-positive NSCLC at ASCO 2026](https://longbridge.com/en/news/287275055.md)